January 2022 Issue | Blood Cancers Today

January 2022

The debut issue of Blood Cancers Today asks whether measurable residual disease is ALL it’s cracked up to be, debates the value of maintenance therapy in acute myeloid leukemia, and reports on research highlights from recent medical meetings.

Viewpoints

Editor's Message

A New Year, a New Publication

Features

News

Case Studies

Choosing Frontline Therapy for Chronic Lymphocytic Leukemia

In the Literature

HLH Is a Possible New CAR T-Cell–Associated Toxicity in Young Patients

Late Mortality After Transplant Has Improved—for Certain Patients

Do c-KIT Mutations Predict Poor Outcomes in Pediatric Core Binding Factor AML?

CANDOR: Comparing KdD to Kd in Relapsed/Refractory Multiple Myeloma

Meeting News

Study REVEALs Thrombotic Complications as Leading Cause of Death in Older Patients with Polycythemia Vera

Response-Based Dose-Reduction Strategy for Ponatinib Optimizes Risk-Benefit Ratio in CP-CML

Pirtobrutinib Shows Promising Efficacy in Previously Treated CLL/SLL

Polatuzumab Vedotin Plus R-CHOP Improves Progression-Free Survival in Newly Diagnosed DLBCL

High Complete Response Rates with Magrolimab Triplet in High-Risk Acute Myeloid Leukemia

Extended GRIFFIN Follow-up Shows Durability of Daratumumab Quadruplet Responses in Transplant-Eligible Myeloma

New Single-Cell Multi-Omic Analysis Shines Light on Mechanisms of TP53-Mutant Myeloid Neoplasms

Long-Term Data Show Cilta-Cel Yields Early, Durable Responses in Relapsed Refractory Multiple Myeloma

Regulatory Actions

FDA Grants Orphan Drug Designation to NKX101 for AML

FDA Approves Abatacept for Graft-Versus-Host Disease Prophylaxis

FDA Approves Daratumumab and Hyaluronidase-fihj Plus Kd for Relapsed/Refractory MM

Nanatinostat and Valganciclovir Receive Orphan Drug Designation for Epstein Barr Virus–Positive DLBCL

Rituximab Plus Chemotherapy Approved for Pediatric Blood Cancers

FDA Places Partial Clinical Hold on Trial of Kura Oncology’s KO-539 in AML

State of the Art

State of the Art: Novel Therapies for Myelofibrosis

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer